Idenix Pharmaceuticals v. Gilead Sciences
Already the largest patent iN- fringement verdict in U.S. history, the $2.5 billion in damages awarded to Merck & Co. Inc.’s Idenix unit could grow by as much as three times the amount assessed by a federal jury in Wilmington, Delaware, on Dec. 15. Stephanie Parker of Jones Day led Idenix’s legal team, joined by her partners Anthony Insogna, Calvin Griffith, Jennifer Swize and others at the firm. John Day, a director of Ashby & Geddes’ intellectual property group, also represented Idenix, along with the firm’s IP group chair Steven Balick and IP director Andrew Mayo.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
